PharmaEssentia: New ET Indication Aims for August Approval, AOP Arbitration Hopes for Settlement
PharmaEssentia expects revenue and profit growth to surpass last year, driven by strong sales of its blood cancer drug Ropeg and anticipated US FDA approval in August for a new indication, Essential Thrombocythemia (ET). The company is also actively pursuing a settlement in its arbitration with European distributor AOP.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 19:23
- 🔍 Collected: May 12, 2026 at 19:32 (8 min after Published)
- 🤖 AI Analyzed: May 12, 2026 at 19:46 (14 min after Collected)
TAIPEI (CNA) — PharmaEssentia Chairman Ko-Chung Lin stated that the company's blood cancer new drug Ropeg has shown outstanding sales performance. Coupled with the expected US FDA approval for its new indication, Essential Thrombocythemia (ET), in August this year, he is optimistic that this year's revenue and profit growth will surpass last year's. Regarding the arbitration with European distributor AOP, PharmaEssentia CEO Lin Kuo-Chung said that efforts are currently focused on reaching a settlement.
PharmaEssentia held a press conference today to share its recent progress in expanding its commercial footprint in the Americas and introduced its core team in the US subsidiary. Canadian pharmaceutical partners and Latin American partners also attended the event in Taiwan.
PharmaEssentia noted that since the US Food and Drug Administration approved Ropeg for the treatment of Polycythemia Vera (PV) in 2021, the number of patients using the drug globally has continued to grow rapidly, with the US market performing particularly well, becoming a significant driver of PharmaEssentia's operational growth.
To meet the rapidly growing demand, PharmaEssentia stated that it plans to expand its marketing and sales teams in 2025, increasing the US team size by 65% to further strengthen market promotion momentum.
Chairman Ko-Chung Lin said that PharmaEssentia expects to achieve important commercial milestones this year, with the most anticipated being the US FDA's approval of Ropeg for the new indication, Essential Thrombocythemia (ET), in August this year. She is optimistic that this year's revenue and profit growth will be even more impressive than last year.
Furthermore, regarding the arbitration dispute between PharmaEssentia and its original distributor AOP, PharmaEssentia announced on May 3 this year that it had filed an appeal with the German Federal Supreme Court (BGH) against the decision of the Higher Regional Court Frankfurt (OLG Frankfurt) to reject the company's application to revoke a partial arbitration award issued by the International Chamber of Commerce (ICC) on February 17, 2025.
Ko-Chung Lin mentioned that the company is considering reclaiming the distribution rights for Ropeg and hopes for progress in negotiations between the two parties this year. Lin Kuo-Chung also stated that efforts are indeed focused on reaching a settlement, and recent negotiations have entered a more advanced stage. (Edited by Huang Kuo-Lun) 1150512
Choose to stand with facts, every sponsorship is a force to protect press freedom.
Download CNA's "First-hand News" APP to stay updated with the latest news.
The text, images, and videos on this website may not be reproduced, publicly broadcast, publicly transmitted, or utilized without authorization.
PharmaEssentia held a press conference today to share its recent progress in expanding its commercial footprint in the Americas and introduced its core team in the US subsidiary. Canadian pharmaceutical partners and Latin American partners also attended the event in Taiwan.
PharmaEssentia noted that since the US Food and Drug Administration approved Ropeg for the treatment of Polycythemia Vera (PV) in 2021, the number of patients using the drug globally has continued to grow rapidly, with the US market performing particularly well, becoming a significant driver of PharmaEssentia's operational growth.
To meet the rapidly growing demand, PharmaEssentia stated that it plans to expand its marketing and sales teams in 2025, increasing the US team size by 65% to further strengthen market promotion momentum.
Chairman Ko-Chung Lin said that PharmaEssentia expects to achieve important commercial milestones this year, with the most anticipated being the US FDA's approval of Ropeg for the new indication, Essential Thrombocythemia (ET), in August this year. She is optimistic that this year's revenue and profit growth will be even more impressive than last year.
Furthermore, regarding the arbitration dispute between PharmaEssentia and its original distributor AOP, PharmaEssentia announced on May 3 this year that it had filed an appeal with the German Federal Supreme Court (BGH) against the decision of the Higher Regional Court Frankfurt (OLG Frankfurt) to reject the company's application to revoke a partial arbitration award issued by the International Chamber of Commerce (ICC) on February 17, 2025.
Ko-Chung Lin mentioned that the company is considering reclaiming the distribution rights for Ropeg and hopes for progress in negotiations between the two parties this year. Lin Kuo-Chung also stated that efforts are indeed focused on reaching a settlement, and recent negotiations have entered a more advanced stage. (Edited by Huang Kuo-Lun) 1150512
Choose to stand with facts, every sponsorship is a force to protect press freedom.
Download CNA's "First-hand News" APP to stay updated with the latest news.
The text, images, and videos on this website may not be reproduced, publicly broadcast, publicly transmitted, or utilized without authorization.